Please provide your email address to receive an email when new articles are posted on . The FDA issued a boxed warning stating denosumab increases severe hypocalcemia risk for adults with advanced CKD ...

A HITHERTO infrequently recognized abnormality in patients with osteoblastic metastases is the occurrence of hypocalcemia. It has usually been held that calcium levels are normal in this situation. 1 ...

The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...

Background A 70-year-old man presented with a smooth lump on his buccal mucosa and right-sided cervical lymphadenopathy. Staging investigations revealed extensive sclerotic bone metastases and the ...

The US Food and Drug Administration (FDA) issued an alert today that cited preliminary evidence for a "substantial risk" for severe and symptomatic hypocalcemia and serious outcomes related to ...

The FDA said it's looking into the risk of severe hypocalcemia among patients on dialysis receiving denosumab (Prolia), citing the potential for severe outcomes, including hospitalization and death.

Worsening CKD was progressively associated with denosumab-induced hypocalcemia warranting emergency treatment. Denosumab use carries a higher risk for emergency hypocalcemia compared with ...

Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States Denosumab is widely used in the treatment of bone metastases ...

Calcium deficiency results in symptoms like muscle spasms, cramping, irregular heartbeats, and bone fractures. People at a greater risk of calcium deficiency include vegetarians, vegans, ...